Shouzhi Fu
Overview
Explore the profile of Shouzhi Fu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
23
Citations
3465
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Tang Y, Wu Y, Zhu F, Yang X, Huang C, Hou G, et al.
Front Med (Lausanne)
. 2021 Jan;
7:615845.
PMID: 33425960
The outbreak of coronavirus disease 2019 (COVID-19) has led to a large and increasing number of patients requiring prolonged mechanical ventilation and tracheostomy. The indication and optimal timing of tracheostomy...
12.
Xu J, Yang X, Huang C, Zou X, Zhou T, Pan S, et al.
Front Med (Lausanne)
. 2021 Jan;
7:607821.
PMID: 33425951
High-flow nasal cannula (HFNC) has been recommended as a suitable choice for the management of coronavirus disease 2019 (COVID-19) patients with acute hypoxemic respiratory failure before mechanical ventilation (MV); however,...
13.
Yang M, Wang S, Fu S, Wu N, Xu X, Sun S, et al.
Br J Pharmacol
. 2020 Dec;
178(4):964-982.
PMID: 33300167
Background And Purpose: Chronic alcohol consumption contributes to contractile dysfunction and unfavourable geometric changes in myocardium, accompanied by altered autophagy and disturbed mitochondrial homeostasis. The E3 ubiquitin ligase Parkin encoded...
14.
Xu J, Yang X, Yang L, Zou X, Wang Y, Wu Y, et al.
Crit Care
. 2020 Jul;
24(1):394.
PMID: 32631393
Background: The global numbers of confirmed cases and deceased critically ill patients with COVID-19 are increasing. However, the clinical course, and the 60-day mortality and its predictors in critically ill...
15.
Wang Y, Zhou F, Zhang D, Zhao J, Du R, Hu Y, et al.
Trials
. 2020 May;
21(1):422.
PMID: 32448345
Background: Coronavirus disease 2019 (COVID-19), caused by a novel corinavirus (later named SARS-CoV-2 virus), was fistly reported in Wuhan, Hubei Province, China towards the end of 2019. Large-scale spread within...
16.
Wu J, Li J, Zhu G, Zhang Y, Bi Z, Yu Y, et al.
Clin J Am Soc Nephrol
. 2020 May;
15(8):1139-1145.
PMID: 32444393
Background And Objectives: Previous reports on the outbreak of coronavirus disease 2019 were on the basis of data from the general population. Our study aimed to investigate the clinical features...
17.
Wang Y, Zhang D, Du G, Du R, Zhao J, Jin Y, et al.
Lancet
. 2020 May;
395(10236):1569-1578.
PMID: 32423584
Background: No specific antiviral drug has been proven effective for treatment of patients with severe coronavirus disease 2019 (COVID-19). Remdesivir (GS-5734), a nucleoside analogue prodrug, has inhibitory effects on pathogenic...
18.
Yu Y, Xu D, Fu S, Zhang J, Yang X, Xu L, et al.
Crit Care
. 2020 May;
24(1):219.
PMID: 32410714
Background: A COVID-19 outbreak started in Wuhan, China, last December and now has become a global pandemic. The clinical information in caring of critically ill patients with COVID-19 needs to...
19.
Lei F, Liu Y, Zhou F, Qin J, Zhang P, Zhu L, et al.
Hepatology
. 2020 May;
72(2):389-398.
PMID: 32359177
Background And Aims: Coronavirus disease 2019 (COVID-19) is a new infectious disease. To reveal the hepatic injury related to this disease and its clinical significance, we conducted a multicenter retrospective...
20.
Zhang P, Zhu L, Cai J, Lei F, Qin J, Xie J, et al.
Circ Res
. 2020 Apr;
126(12):1671-1681.
PMID: 32302265
Rationale: Use of ACEIs (angiotensin-converting enzyme inhibitors) and ARBs (angiotensin II receptor blockers) is a major concern for clinicians treating coronavirus disease 2019 (COVID-19) in patients with hypertension. Objective: To...